Vicebio has announced its aim to accelerate the development of novel vaccines against life-threatening respiratory viral infections using its novel molecular clamp technology platform.
The technology has been developed by Professor Paul Young, Dr Daniel Watterson, Dr Keith Chappell and their respective groups at The University of Queensland (UQ) and licensed to Vicebio by UniQuest, the commercialisation company of UQ.
Medicxi has so far committed €18m to progress this technology into the clinic, while Dr Emmanuel Hanon – the former head of vaccines R&D at GSK – has been appointed as chief executive officer at the company.
